HER2newC apoptosis inducer - IcanoMAB
Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator MAB Discovery
- Developer IcanoMAB
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Breast cancer